View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsKolinpharma 過去の業績過去 基準チェック /26Kolinpharmaは、平均年間24.9%の収益成長を遂げていますが、 Personal Products業界の収益は、年間 成長しています。収益は、平均年間10.3% 16.1%収益成長率で 成長しています。 Kolinpharmaの自己資本利益率は4.1%であり、純利益率は2.2%です。主要情報24.91%収益成長率23.29%EPS成長率Personal Products 業界の成長13.59%収益成長率16.15%株主資本利益率4.09%ネット・マージン2.19%前回の決算情報31 Dec 2022最近の業績更新Reported Earnings • Mar 24Full year 2022 earnings releasedFull year 2022 results: Revenue: €15.6m (up 23% from FY 2021). Net income: €342.3k (down 46% from FY 2021). Profit margin: 2.2% (down from 5.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.8% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Personal Products industry in Italy.Reported Earnings • Oct 03First half 2022 earnings released: EPS: €0 (vs €0.23 in 1H 2021)First half 2022 results: EPS: €0 (down from €0.23 in 1H 2021). Revenue: €6.90m (up 13% from 1H 2021). Net loss: €26.9k (down 107% from profit in 1H 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Personal Products industry in Italy.Reported Earnings • Oct 01First half 2021 earnings releasedThe company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €6.53m (up 110% from 1H 2020). Net income: €374.9k (up €502.6k from 1H 2020). Profit margin: 5.7% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue.Reported Earnings • Apr 01Full year 2020 earnings releasedThe company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: €9.52m (down 4.8% from FY 2019). Net income: €642.4k (up 8.6% from FY 2019). Profit margin: 6.7% (up from 5.9% in FY 2019). The increase in margin was driven by lower expenses.すべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Jun 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €9.45, the stock trades at a trailing P/E ratio of 44.4x. Average forward P/E is 23x in the Personal Products industry in Italy. Total returns to shareholders of 6.4% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €7.99 per share.分析記事 • Jun 17Kolinpharma (BIT:KIP) Is Looking To Continue Growing Its Returns On CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Reported Earnings • Mar 24Full year 2022 earnings releasedFull year 2022 results: Revenue: €15.6m (up 23% from FY 2021). Net income: €342.3k (down 46% from FY 2021). Profit margin: 2.2% (down from 5.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.8% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Personal Products industry in Italy.Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improved over the past weekAfter last week's 19% share price gain to €8.40, the stock trades at a trailing P/E ratio of 58x. Average forward P/E is 21x in the Personal Products industry in Italy. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €15.25 per share.分析記事 • Dec 01What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?Kolinpharma S.p.A. ( BIT:KIP ), is not the largest company out there, but it saw significant share price movement...Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Chairman of the Board of Statutory Auditors Pierluigi Pipolo was the last director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 03First half 2022 earnings released: EPS: €0 (vs €0.23 in 1H 2021)First half 2022 results: EPS: €0 (down from €0.23 in 1H 2021). Revenue: €6.90m (up 13% from 1H 2021). Net loss: €26.9k (down 107% from profit in 1H 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Personal Products industry in Italy.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Chairman of the Board of Statutory Auditors Pierluigi Pipolo was the last director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Price Target Changed • Apr 14Price target increased to €13.45Up from €12.38, the current price target is an average from 2 analysts. New target price is 60% above last closing price of €8.42. Stock is up 2.7% over the past year.Buying Opportunity • Apr 06Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 7.7%. The fair value is estimated to be €11.05, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company has become profitable.Buying Opportunity • Feb 04Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 6.1%. The fair value is estimated to be €11.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% per annum over the last 3 years. The company has become profitable over the last 3 years.Reported Earnings • Oct 01First half 2021 earnings releasedThe company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €6.53m (up 110% from 1H 2020). Net income: €374.9k (up €502.6k from 1H 2020). Profit margin: 5.7% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue.Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 26% share price gain to €10.30, the stock trades at a trailing P/E ratio of 26.3x. Average forward P/E is 32x in the Personal Products industry in Europe. Total returns to shareholders of 48% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €17.98 per share.分析記事 • Aug 25An Intrinsic Calculation For Kolinpharma S.p.A. (BIT:KIP) Suggests It's 46% UndervaluedDoes the August share price for Kolinpharma S.p.A. ( BIT:KIP ) reflect what it's really worth? Today, we will estimate...分析記事 • Jun 08We Think Kolinpharma (BIT:KIP) Can Stay On Top Of Its DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • May 21Do Kolinpharma's (BIT:KIP) Earnings Warrant Your Attention?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...分析記事 • May 03Is There An Opportunity With Kolinpharma S.p.A.'s (BIT:KIP) 35% Undervaluation?Today we will run through one way of estimating the intrinsic value of Kolinpharma S.p.A. ( BIT:KIP ) by taking the...分析記事 • Apr 13Some Shareholders Feeling Restless Over Kolinpharma S.p.A.'s (BIT:KIP) P/E RatioWith a price-to-earnings (or "P/E") ratio of 22.3x Kolinpharma S.p.A. ( BIT:KIP ) may be sending bearish signals at the...Reported Earnings • Apr 01Full year 2020 earnings releasedThe company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: €9.52m (down 4.8% from FY 2019). Net income: €642.4k (up 8.6% from FY 2019). Profit margin: 6.7% (up from 5.9% in FY 2019). The increase in margin was driven by lower expenses.分析記事 • Feb 20What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?Kolinpharma S.p.A. ( BIT:KIP ), might not be a large cap stock, but it maintained its current share price over the past...Is New 90 Day High Low • Jan 11New 90-day high: €8.52The company is up 2.0% from its price of €8.36 on 13 October 2020. The Italian market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €21.98 per share.分析記事 • Dec 28Is Weakness In Kolinpharma S.p.A. (BIT:KIP) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?It is hard to get excited after looking at Kolinpharma's (BIT:KIP) recent performance, when its stock has declined 7.1...Is New 90 Day High Low • Dec 18New 90-day low: €7.96The company is down 8.0% from its price of €8.64 on 18 September 2020. The Italian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.27 per share.分析記事 • Nov 22These 4 Measures Indicate That Kolinpharma (BIT:KIP) Is Using Debt Reasonably WellLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Is New 90 Day High Low • Oct 30New 90-day low: €8.00The company is down 7.0% from its price of €8.60 on 31 July 2020. The Italian market is down 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Personal Products industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.68 per share.Price Target Changed • Oct 17Price target lowered to €11.69Down from €13.05, the current price target is an average from 2 analysts. The new target price is 40% above the current share price of €8.34. As of last close, the stock is down 18% over the past year.Is New 90 Day High Low • Oct 13New 90-day low: €8.36The company is down 5.0% from its price of €8.76 on 15 July 2020. The Italian market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €21.65 per share.お知らせ • Jul 31An undisclosed buyer acquired 12.2% stake in Kolinpharma S.p.A. (BIT:KIP) from Rita Paola Petrelli.An undisclosed buyer acquired 12.2% stake in Kolinpharma S.p.A. (BIT:KIP) from Rita Paola Petrelli on April 22, 2020. Pursuant to the terms of the transaction, Rita Paola Petrelli sold 0.2 million Kolinpharma shares. As a result of the transaction, stake of Rita Paola Petrelli has decreased from 71.82% to 59.62%. An undisclosed buyer completed the acquisition of 12.2% stake in Kolinpharma S.p.A. (BIT:KIP) from Rita Paola Petrelli on April 22, 2020.収支内訳Kolinpharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BIT:KIP 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Dec 221605030 Sep 221405030 Jun 221305031 Mar 221305031 Dec 211315030 Sep 211314030 Jun 211314031 Mar 211113031 Dec 201013030 Sep 20913030 Jun 20913031 Mar 201013031 Dec 191013030 Sep 191003030 Jun 19902031 Mar 19902031 Dec 18902030 Sep 18800030 Jun 18701031 Mar 18601031 Dec 17501031 Dec 16400031 Dec 152-110質の高い収益: KIPは 高品質の収益 を持っています。利益率の向上: KIPの現在の純利益率 (2.2%)は、昨年(5%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: KIP過去 5 年間で収益を上げており、収益は年間24.9%増加しています。成長の加速: KIPは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: KIPは過去 1 年間で収益成長率がマイナス ( -46.3% ) となったため、 Personal Products業界平均 ( 2.8% ) と比較することが困難です。株主資本利益率高いROE: KIPの 自己資本利益率 ( 4.1% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHousehold 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/11/01 17:49終値2023/09/27 00:00収益2022/12/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kolinpharma S.p.A. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Luigi TardellaEnVent Capital Markets LimitedLuisa PrimiIR Top Consulting S.r.l.
Reported Earnings • Mar 24Full year 2022 earnings releasedFull year 2022 results: Revenue: €15.6m (up 23% from FY 2021). Net income: €342.3k (down 46% from FY 2021). Profit margin: 2.2% (down from 5.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.8% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Personal Products industry in Italy.
Reported Earnings • Oct 03First half 2022 earnings released: EPS: €0 (vs €0.23 in 1H 2021)First half 2022 results: EPS: €0 (down from €0.23 in 1H 2021). Revenue: €6.90m (up 13% from 1H 2021). Net loss: €26.9k (down 107% from profit in 1H 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Personal Products industry in Italy.
Reported Earnings • Oct 01First half 2021 earnings releasedThe company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €6.53m (up 110% from 1H 2020). Net income: €374.9k (up €502.6k from 1H 2020). Profit margin: 5.7% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue.
Reported Earnings • Apr 01Full year 2020 earnings releasedThe company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: €9.52m (down 4.8% from FY 2019). Net income: €642.4k (up 8.6% from FY 2019). Profit margin: 6.7% (up from 5.9% in FY 2019). The increase in margin was driven by lower expenses.
Valuation Update With 7 Day Price Move • Jun 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €9.45, the stock trades at a trailing P/E ratio of 44.4x. Average forward P/E is 23x in the Personal Products industry in Italy. Total returns to shareholders of 6.4% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €7.99 per share.
分析記事 • Jun 17Kolinpharma (BIT:KIP) Is Looking To Continue Growing Its Returns On CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Reported Earnings • Mar 24Full year 2022 earnings releasedFull year 2022 results: Revenue: €15.6m (up 23% from FY 2021). Net income: €342.3k (down 46% from FY 2021). Profit margin: 2.2% (down from 5.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.8% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Personal Products industry in Italy.
Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improved over the past weekAfter last week's 19% share price gain to €8.40, the stock trades at a trailing P/E ratio of 58x. Average forward P/E is 21x in the Personal Products industry in Italy. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €15.25 per share.
分析記事 • Dec 01What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?Kolinpharma S.p.A. ( BIT:KIP ), is not the largest company out there, but it saw significant share price movement...
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Chairman of the Board of Statutory Auditors Pierluigi Pipolo was the last director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 03First half 2022 earnings released: EPS: €0 (vs €0.23 in 1H 2021)First half 2022 results: EPS: €0 (down from €0.23 in 1H 2021). Revenue: €6.90m (up 13% from 1H 2021). Net loss: €26.9k (down 107% from profit in 1H 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Personal Products industry in Italy.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Chairman of the Board of Statutory Auditors Pierluigi Pipolo was the last director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Price Target Changed • Apr 14Price target increased to €13.45Up from €12.38, the current price target is an average from 2 analysts. New target price is 60% above last closing price of €8.42. Stock is up 2.7% over the past year.
Buying Opportunity • Apr 06Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 7.7%. The fair value is estimated to be €11.05, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company has become profitable.
Buying Opportunity • Feb 04Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 6.1%. The fair value is estimated to be €11.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% per annum over the last 3 years. The company has become profitable over the last 3 years.
Reported Earnings • Oct 01First half 2021 earnings releasedThe company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €6.53m (up 110% from 1H 2020). Net income: €374.9k (up €502.6k from 1H 2020). Profit margin: 5.7% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue.
Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 26% share price gain to €10.30, the stock trades at a trailing P/E ratio of 26.3x. Average forward P/E is 32x in the Personal Products industry in Europe. Total returns to shareholders of 48% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €17.98 per share.
分析記事 • Aug 25An Intrinsic Calculation For Kolinpharma S.p.A. (BIT:KIP) Suggests It's 46% UndervaluedDoes the August share price for Kolinpharma S.p.A. ( BIT:KIP ) reflect what it's really worth? Today, we will estimate...
分析記事 • Jun 08We Think Kolinpharma (BIT:KIP) Can Stay On Top Of Its DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • May 21Do Kolinpharma's (BIT:KIP) Earnings Warrant Your Attention?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
分析記事 • May 03Is There An Opportunity With Kolinpharma S.p.A.'s (BIT:KIP) 35% Undervaluation?Today we will run through one way of estimating the intrinsic value of Kolinpharma S.p.A. ( BIT:KIP ) by taking the...
分析記事 • Apr 13Some Shareholders Feeling Restless Over Kolinpharma S.p.A.'s (BIT:KIP) P/E RatioWith a price-to-earnings (or "P/E") ratio of 22.3x Kolinpharma S.p.A. ( BIT:KIP ) may be sending bearish signals at the...
Reported Earnings • Apr 01Full year 2020 earnings releasedThe company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: €9.52m (down 4.8% from FY 2019). Net income: €642.4k (up 8.6% from FY 2019). Profit margin: 6.7% (up from 5.9% in FY 2019). The increase in margin was driven by lower expenses.
分析記事 • Feb 20What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?Kolinpharma S.p.A. ( BIT:KIP ), might not be a large cap stock, but it maintained its current share price over the past...
Is New 90 Day High Low • Jan 11New 90-day high: €8.52The company is up 2.0% from its price of €8.36 on 13 October 2020. The Italian market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €21.98 per share.
分析記事 • Dec 28Is Weakness In Kolinpharma S.p.A. (BIT:KIP) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?It is hard to get excited after looking at Kolinpharma's (BIT:KIP) recent performance, when its stock has declined 7.1...
Is New 90 Day High Low • Dec 18New 90-day low: €7.96The company is down 8.0% from its price of €8.64 on 18 September 2020. The Italian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.27 per share.
分析記事 • Nov 22These 4 Measures Indicate That Kolinpharma (BIT:KIP) Is Using Debt Reasonably WellLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Is New 90 Day High Low • Oct 30New 90-day low: €8.00The company is down 7.0% from its price of €8.60 on 31 July 2020. The Italian market is down 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Personal Products industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.68 per share.
Price Target Changed • Oct 17Price target lowered to €11.69Down from €13.05, the current price target is an average from 2 analysts. The new target price is 40% above the current share price of €8.34. As of last close, the stock is down 18% over the past year.
Is New 90 Day High Low • Oct 13New 90-day low: €8.36The company is down 5.0% from its price of €8.76 on 15 July 2020. The Italian market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €21.65 per share.
お知らせ • Jul 31An undisclosed buyer acquired 12.2% stake in Kolinpharma S.p.A. (BIT:KIP) from Rita Paola Petrelli.An undisclosed buyer acquired 12.2% stake in Kolinpharma S.p.A. (BIT:KIP) from Rita Paola Petrelli on April 22, 2020. Pursuant to the terms of the transaction, Rita Paola Petrelli sold 0.2 million Kolinpharma shares. As a result of the transaction, stake of Rita Paola Petrelli has decreased from 71.82% to 59.62%. An undisclosed buyer completed the acquisition of 12.2% stake in Kolinpharma S.p.A. (BIT:KIP) from Rita Paola Petrelli on April 22, 2020.